. Author manuscript; available in PMC: 2018 Mar 1.

Published in final edited form as: J Urol. 2016 Nov 10;197(3 Pt 2):931–936. doi: 10.1016/j.juro.2016.09.072

Table 1.

Testicular adrenal rest tumor prevalence in males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and phenotypic subclassification and medication dose in those with and without tumor

	Age (yrs)
	0–5	5–12	Greater than 12	Overall
No. pts	7	9	19	35
No. TART (%)^*	0	1 (11)	4 (21)	5 (14)
No. CAH type:
Salt-wasting	6	17	14	27
Simple virilizing	1	1	3	5
Nonclassic	0	1	2	3
Mean ± SD hydrocortisone dose (mg/m²/day):
TART neg	16.2 ± 4.7	15.7 ± 3.1	15.4 ± 6.3	15.5 ± 5.2
TART pos	–	19.7	16.6 ± 2.2	17.2 ± 2.4
Mean ± SD fludrocortisone dose (mg/day):
TART neg	0.08 ± 0.04	0.08 ± 0.04	0.06 ± 0.05	0.07 ± 0.05
TART pos	–	0.2	0.15 ± 0.06	0.16 ± 0.05^†

Age trend did not reach statistical significance (p = 0.16).

^†

Significantly higher vs patients without testicular adrenal rest tumor (p <0.01).